Online citations, reference lists, and bibliographies.
← Back to Search

Aggressive Multimodality Therapy For Malignant Pleural Mesothelioma.

T. Rice, D. Adelstein, T. Kirby, M. G. Saltarelli, S. Murthy, M. A. Van Kirk, H. Wiedemann, J. K. Weick
Published 1994 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Nineteen patients with clinical stage I malignant pleural mesothelioma were treated with aggressive multimodality therapy. Nine patients underwent pleurectomy and decortication followed by immediate intrapleural chemotherapy with cisplatin and mitomycin C. Ten patients required pleuropneumonectomy followed within 1 week to 2 weeks by intrapleural administration of cisplatin (100 mg). Four to 8 weeks after operation, 15 patients underwent postoperative adjuvant cisplatin-based systemic chemotherapy. There were three postoperative complications (16%) requiring reoperation and one postoperative death (5%). Intrapleural chemotherapy was well tolerated with no complications. Systemic chemotherapy was poorly tolerated, and there was one chemotherapy-related death. Sixteen patients (84%) experienced good to excellent palliation. Three patients are currently alive with no evidence of recurrent disease at 10, 35, and 43 months. The median overall survival was 13 months and the median disease-free survival, 11 months. Overall and disease-free 3-year survivals were 17% and 22%, respectively. Patients with epithelial malignant pleural mesothelioma had significantly better overall survival (p = 0.037) and disease-free survival (p = 0.02) than patients with sarcomatous or biphasic malignant pleural mesothelioma. We conclude that despite major toxicity, in select patients with clinical stage I malignant pleural mesothelioma, aggressive multimodality therapy offers effective palliation and occasional long-term disease-free survival.
This paper references
10.1002/1097-0142(19940101)73:1<79::AID-CNCR2820730115>3.0.CO;2-0
High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses
R. Lerza (1994)
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
A. Chahinian (1984)
10.1200/JCO.1991.9.4.649
A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
S. Kirmani (1991)
10.1016/1010-7940(89)90056-0
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
R. Achatzy (1989)
10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A
New strategies are needed in diffuse malignant mesothelioma
Kasi S. Sridhar (1992)
10.1016/S0022-5223(19)38932-9
Surgical treatment of pleural mesothelioma.
P. McCormack (1982)
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
R. Dedrick (1978)
10.1016/S0022-5223(19)36578-X
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.
D. Sugarbaker (1991)
10.1200/JCO.1989.7.9.1327
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
B. Reichman (1989)
10.1016/0277-5379(91)90487-X
Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma.
S. Pyrhönen (1991)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1200/JCO.1992.10.6.1001
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
V. Rusch (1992)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1016/S0003-4975(10)64593-6
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
10.1200/JCO.1987.5.10.1607
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
S. Howell (1987)
10.1177/31.11.6619538
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
D. Hedley (1983)
10.7326/0003-4819-99-3-429_1
Manual for Staging of Cancer
O. Beahrs (1992)
10.1002/CYTO.990050502
Convention on nomenclature for DNA cytometry
W. Hiddemann (1984)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
10.1016/0046-8177(89)90072-5
Flow cytometric analysis of malignant pleural mesotheliomas.
G. Burmer (1989)
Ackerman's surgical pathology
L. V. Ackerman (1974)
10.1002/1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma
M. Markman (1986)



This paper is referenced by
Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
F. Colaut (2004)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1093/annonc/mdj912
Malignant pleural mesothelioma.
P. Baas (1998)
10.1378/CHEST.126.4.1318
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
M. Pistolesi (2004)
10.1007/s00259-010-1704-x
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival
V. Gerbaudo (2010)
10.1007/s13566-014-0142-y
Impact of intensity-modulated radiation therapy on outcomes for malignant pleural mesothelioma treated with trimodality therapy
E. Murphy (2014)
10.1111/j.1440-1843.2005.00714.x
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma
D. Sterman (2005)
10.1016/j.ijrobp.2011.11.057
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
P. Patel (2012)
10.1053/J.OPTECHSTCVS.2006.02.002
Treatment of Malignant Pleural Mesothelioma: Pleurectomy with Adjuvant Therapy
R. Flores (2006)
10.1007/s00063-002-1181-5
Prognose, Staging und Therapie des malignen Pleuramesothelioms
W. Neumeister (2002)
10.1007/978-1-84996-492-0_47
Malignant Pleural Mesothelioma: Patient Selection for Pleurectomy
R. Flores (2011)
10.1016/J.ATHORACSUR.2004.01.034
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1007/BF02912122
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma
K. Takahashi (2001)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.2995/JACSURG.23.802
Evaluation of recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma-A clinical study of 10 cases from Okayama Rousai Hospital-
Hideyuki Nishi (2009)
10.3816/CLC.2009.n.005
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
A. Tsao (2009)
10.1097/JTO.0b013e318031d05c
Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study
M. Lucchi (2007)
10.1097/00063198-200007000-00003
Management of malignant pleural mesothelioma: a critical review
Y. Lee (2000)
STRATEGIES TO ENHANCE EFFICACY OF ONCOLYTIC VIROTHERAPY
S. Pesonen (2016)
10.1016/S1547-4127(04)00108-2
External beam radiation therapy for the treatment of pleural mesothelioma.
E. Baldini (2004)
10.1007/0-387-28274-2_44
Preoperative Chemotherapy and Surgery
E. Vallières (2005)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1097/01.LBR.0000011079.00225.DF
Treatment of Mesotheliomatous Pleural Effusion: Experimental Therapy versus Thoracoscopic Talc Poudrage? Pro: Talc Poudrage Therapy
Y. Aelony (2001)
10.1097/MNM.0b013e3283653862
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography–computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication
A. Billè (2013)
10.1007/978-1-59745-225-0_24
Hyperthermic Intrapleural Chemotherapy in Pleural Malignancy
Frans A. N. Zoetmulder (2007)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/j.jtcvs.2010.09.032
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study.
I. Opitz (2011)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1016/S0960-7404(98)00019-X
Malignant pleural mesothelioma: a problematic review.
T. L. Moskal (1998)
10.1053/j.semtcvs.2008.11.002
Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.
A. Mujoomdar (2008)
10.1007/S11912-002-0006-2
Current therapy for malignant mesothelioma
W. Smythe (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar